Luminex Corporation and ViroNovative Announce License Agreement for Human Metapneumovirus Rights
July 14 2008 - 12:07PM
Business Wire
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in
multiplexed solutions, and ViroNovative BV today announced that the
companies have signed a licensing agreement that gives Luminex
worldwide rights to use ViroNovative�s human metapneumovirus (hMPV)
intellectual property in the xTAG Respiratory Viral Panel (RVP).
Under the terms of the agreement, rights to ViroNovative�s hMPV
intellectual property will be extended to Luminex�s distributors
and end-user customers around the world. �We are pleased to
announce this license agreement in place with ViroNovative for
human metapneumovirus,� said Jeremy Bridge-Cook, vice president of
Luminex Molecular Diagnostics. �This virus is of increasing concern
to healthcare providers worldwide. Having this license as part of
our xTAG RVP assay is important to us as it allows our customers to
use this cutting-edge test without the need to individually secure
rights to this intellectual property.� Luminex�s xTAG RVP received
510(k) clearance from the U.S. Food and Drug Administration (FDA)
on January 3, 2008. The test was cleared for the detection and
identification of 12 viruses and viral subtypes that are together
responsible for more than 85 percent of respiratory viral
infections. xTAG RVP is the first multiplexed nucleic acid test for
respiratory viruses cleared for in vitro diagnostic use by the FDA
and is the first and only test cleared by FDA for the detection of
hMPV. �The Luminex platform has achieved remarkable market
penetration, so we are delighted to have licensed Luminex Molecular
Diagnostics rights to hMPV,� said James Simon, chief operating
officer of ViroNovative BV. �This agreement will help promote
diagnosis of hMPV, an important virus that infects the respiratory
tract and causes significant clinical impact in humans, especially
in young children.� Human metapneumovirus was first identified in
2001. The virus, which is found worldwide, causes flu-like symptoms
and is a cause of significant upper and lower respiratory
infections in all age groups. It is thought to be the second most
common cause of lower respiratory infection in young children.
About Luminex Corporation Luminex Corporation develops,
manufactures and markets proprietary biological testing
technologies with applications throughout the diagnostic and life
sciences industries. The Company�s xMAP� multiplex solutions
include an open-architecture, multi-analyte technology platform
that delivers fast, accurate and cost-effective bioassay results to
markets as diverse as pharmaceutical drug discovery, clinical
diagnostics and biomedical research, including the genomics and
proteomics markets. The Company�s xMAP technology is sold worldwide
and is already in use in leading clinical laboratories as well as
major pharmaceutical, diagnostic and biotechnology companies.
Further information on Luminex Corporation or xMAP technology can
be obtained at www.luminexcorp.com. About ViroNovative BV
ViroNovative BV is dedicated to providing a complete solution to
human Metapneumovirus (hMPV), a virus discovered in 2001 by the
team of Prof Dr A.D.M.E. Osterhaus at the Erasmus Medical Centre.
To this end, ViroNovative is promoting the development of
diagnostics and vaccines for the detection and prevention of hMPV
infection. ViroNovative is a member of Viroventures, an
organization in which ViroNovative collaborates with affiliates
Viroscope and ViroClinics, sharing resources and expertise to
combat infectious diseases.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Luminex Corporation (NASDAQ): 0 recent articles
More Luminex Corporation News Articles